Chain-Terminating Dinucleoside Tetraphosphates Are Substrates for DNA Polymerization by Human Immunodeficiency Virus Type 1 Reverse Transcriptase with Increased Activity against Thymidine Analogue-Resistant Mutants
Authors:
- 1 November 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (11) , 3607-3614
Abstract
Nucleoside reverse transcriptase inhibitors are an important class of drugs for treatment of human immunodeficiency virus type 1 (HIV-1) infection. Resistance to these drugs is often the result of mutations that increase the transfer of chain-terminating nucleotides from blocked DNA termini to a nucleoside triphosphate acceptor, resulting in the generation of an unblocked DNA chain and synthesis of a dinucleoside polyphosphate containing the chain-terminating deoxynucleoside triphosphate analogue. We have synthesized and purified several dinucleoside tetraphosphates (ddAp 4 ddA, ddCp 4 ddC, ddGp 4 ddG, ddTp 4 ddT, Ap 4 ddG, 2′(3′)- O -( N -methylanthraniloyl)-Ap 4 ddG, and AppNHppddG) and show that these compounds can serve as substrates for DNA chain elongation and termination resulting in inhibition of DNA synthesis. Thymidine analogue-resistant mutants of reverse transcriptase are up to 120-fold more sensitive to inhibition by these compounds than is wild-type enzyme. Drugs based on the dinucleoside tetraphosphate structure could delay or prevent the emergence of mutants with enhanced primer unblocking activity. In addition, such drugs could suppress the resistance phenotype of mutant HIV-1 that is present in individuals infected with resistant virus.Keywords
This publication has 35 references indexed in Scilit:
- Suppression of Multidrug-resistant HIV-1 Reverse Transcriptase Primer Unblocking Activity by α-Phosphate-modified Thymidine AnaloguesJournal of Molecular Biology, 2005
- Intracellular Substrates for the Primer-Unblocking Reaction by Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Detection and Quantitation in Extracts from Quiescent- and Activated-Lymphocyte SubpopulationsAntimicrobial Agents and Chemotherapy, 2005
- Effects of Primer-Template Sequence on ATP-dependent Removal of Chain-terminating Nucleotide Analogues by HIV-1 Reverse TranscriptaseJournal of Biological Chemistry, 2004
- Probing the Molecular Mechanisms of AZT Drug Resistance Mediated by HIV-1 Reverse Transcriptase Using a Transient Kinetic AnalysisBiochemistry, 2003
- Effects of Dipeptide Insertions between Codons 69 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on Primer Unblocking, Deoxynucleoside Triphosphate Inhibition, and DNA Chain ElongationJournal of Virology, 2003
- ATP-Dependent Removal of Nucleoside Reverse Transcriptase Inhibitors by Human Immunodeficiency Virus Type 1 Reverse TranscriptaseAntimicrobial Agents and Chemotherapy, 2002
- Effects of Specific Zidovudine Resistance Mutations and Substrate Structure on Nucleotide-Dependent Primer Unblocking by Human Immunodeficiency Virus Type 1 Reverse TranscriptaseAntimicrobial Agents and Chemotherapy, 2002
- Correlation between Viral Resistance to Zidovudine and Resistance at the Reverse Transcriptase Level for a Panel of Human Immunodeficiency Virus Type 1 MutantsJournal of Virology, 2001
- Biochemical Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to StavudineAntimicrobial Agents and Chemotherapy, 2001
- HIV-1 Reverse Transcriptase Purified from a Recombinant Strain of Escherichia coliAIDS Research and Human Retroviruses, 1990